USPTO trademark

LYMZUL

RegisteredUSPTOWord markClass 5

"LYMZUL" is a word mark owned by Provepharm Life Solutions, filed at the USPTO on April 7, 2023. It is registered and covers class 5 (Pharmaceuticals).

View Provepharm Life Solutions portfolioGet this data via the API
Official USPTO record
LYMZUL trademark as filed
As filed with the USPTO
Status
Registered
Since January 7, 2025
Filed
April 7, 2023
Registered
January 7, 2025
Priority date
April 7, 2023
Claimed from France
Application no.
97877503
Registration no.
7637835
Office
USPTO
United States Patent and Trademark Office
Mark type
Word mark
1 class
Ownership

Who owns LYMZUL

The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.

Owner

Provepharm Life Solutions

Marseille, France

42 trademarks in the portfolioView company

Representative

Kaitlyn M. Garvin

Saunders & Silverstein LLP

Goods and services

What the mark covers

The products and services LYMZUL is filed for, grouped by Nice class.

  • Pharmaceutical preparations for marking tissue by injection in surgery and internal medicine, for marking tissue of the digestive system by oral, anal or injectable administration, for oral and topical antiseptic treatment, for marking and functional verification of gynecological and urological systems by instillation, injection or local application; chemical preparations for medical use for marking tissue by injection in surgery and internal medicine, for marking tissue of the digestive system by oral, anal or injectable administration, for oral and topical antiseptic treatment, for marking and functional verification of gynecological and urological systems by instillation, injection or local application; injectable pharmaceutical solutions for use as a marker during gastrointestinal endoscopy; injectable pharmaceutical solutions used as a contrast solution for medical imaging procedures; injectable pharmaceutical solutions for medical diagnostic purposes for viewing and marking tissue; injectable pharmaceutical solutions used as an aid in visualization of topographic irregularities and in delineation of polypoid or flat lesions, including adenomas; injectable pharmaceutical solutions used for polyps or lesions resection medicines for tissue staining; injectable pharmaceutical solutions for use as a marker during visceral surgery; injectable pharmaceutical solutions for the detection of amniotic fluid leaks; injectable pharmaceutical solutions for use as a marker during cystoscopy and ureteral catheterization; injectable pharmaceutical solutions for use as a marker during vessel delineation and tumor localization procedures; clinical medical reagents; synthetic peptides for pharmaceutical use, namely, for cancer treatments, immunotherapy, cell therapy, antivirals and antibiotics; phytotherapy preparations for medical use; diagnostic preparations in vials for medical use; drug delivery agents in the form of injectable compounds being pharmaceutical solutions in pre-filled vials that facilitate the delivery of pharmaceutical preparations; pre-filled syringes for medical and clinical purposes, sold filled with injectable pharmaceutical solutions for marking tissue by injection application in surgery and internal medicine, for marking tissue of the digestive system by oral, anal or injectable, for the antiseptic treatment orally or topically, for marking and functional verification gynecological and urological systems, by instillation, injection or local application

History

What has happened so far

Steps recorded by the USPTO, newest first.

  1. Notice of registration confirmation emailed
  2. Registered-principal register
  3. Official gazette publication confirmation e-mailed
  4. Published for opposition
  5. Notification of notice of publication e-mailed
  6. Approved for pub - principal register
  7. Teas/email correspondence entered
  8. Correspondence received in law office
  9. Assigned to lie
  10. Teas response to office action received

6 earlier steps on the official record.

Disputes

Oppositions and cancellations

Proceedings recorded against this mark by the USPTO. Reported as recorded, not legal advice.

FAQ

About LYMZUL

Who owns the trademark "LYMZUL"?

The USPTO trademark "LYMZUL" (application 97877503) is owned by Provepharm Life Solutions.

What is the status of "LYMZUL"?

Its status at the USPTO is: registered.

When was "LYMZUL" registered?

It was registered on January 7, 2025.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull LYMZUL and marks like it into your own product with one request.

  • GET/v1/trademarks/{id}

    The full record: owners, classes, dates and images

  • GET/v1/trademarks/{id}/events

    Every step in the office history

  • GET/v1/proceedings?trademark_id={id}

    Oppositions and cancellations against the mark

Get API keyView docs
GET /v1/trademarks/{id}
ID=tm_019d2b91-8cf5-7573-aca9-b5b2e814e7cd
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"
Response
{
  "id": "tm_019d2b91-8cf5-7573-aca9-b5b2e814e7cd",
  "object": "trademark",
  "mark_text": "LYMZUL",
  "status": {
    "primary": "active",
    "stage": "registered"
  },
  "office_code": "US",
  "application_number": "97877503",
  "filing_date": "2023-04-07",
  "nice_classes": [
    5
  ],
  "owners": [
    {
      "name": "PROVEPHARM LIFE SOLUTIONS",
      "entity_id": "ent_019eb70a-f92b-715b-8e14-48c91232b6bd"
    }
  ]
}